Vimarsana
Biggest News Aggregation in the World

Page 4 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Merck Sharp Today - Breaking & Trending Today

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference - Vimarsana News

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 -- LAVA Therapeutics N.V. , a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of...

Cancer vaccines, melanoma, and mRNA Covid technology - Vimarsana News

Cancer vaccines, melanoma, and mRNA Covid technology

Given the Scottish political shenanigans of the past ten days, you could be forgiven for missing a rather exciting developing in cancer research. On…

Analyzing Cocrystal Pharma (NASDAQ:COCP) & Milestone Pharmaceuticals (NASDAQ:MIST) - Vimarsana News

Analyzing Cocrystal Pharma (NASDAQ:COCP) & Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Cocrystal Pharma (NASDAQ:COCP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Insider & Institutional Ownership 86.2% of Milestone […]

Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria - Vimarsana News

Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria

Recent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK inhibitors unless there is no other alternative.

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates - Vimarsana News

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational...